Equator Therapeutics

Equator Therapeutics is pioneering a novel approach to obesity and metabolic disease by pharmacologically stimulating mitochondrial thermogenesis, a natural calorie-burning process. The company's core technology platform enables the direct measurement and high-throughput screening of compounds that activate specific mitochondrial proteins to induce heat production. With a strong scientific foundation published in top-tier journals and an experienced leadership team, Equator is advancing a pre-clinical pipeline with the potential to address a massive, underserved market. The company is a private, pre-revenue biotech positioned at the intersection of mitochondrial biology and metabolic therapeutics.

Proprietary platform for direct electrophysiological measurement and high-throughput screening of compounds that activate mitochondrial thermogenesis via proteins like the ADP/ATP carrier (AAC) and UCP1.

Equator competes in the crowded obesity drug market, currently dominated by GLP-1/GIP agonists from Novo Nordisk and Eli Lilly. Its primary differentiation is its novel mechanism targeting energy expenditure rather than appetite. It also faces potential competition from other companies exploring mitochondrial uncoupling, though its direct electrophysiology platform is a claimed unique advantage.